

**CORRECTION**

**Open Access**



# Correction to: The aluminium-[<sup>18</sup>F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules

Stephen J. Archibald<sup>1,2,3</sup> and Louis Allott<sup>1,2,3\*</sup>

The original article can be found online at <https://doi.org/10.1186/s41181-021-00141-0>.

\*Correspondence: [louis.allott@hull.ac.uk](mailto:louis.allott@hull.ac.uk)  
<sup>1</sup> Positron Emission Tomography Research Centre, Faculty of Health Sciences, University of Hull, Cottingham Road, Kingston upon Hull HU6 7RX, UK  
 Full list of author information is available at the end of the article

**Correction to: EJNMMI Radiopharm. Chem. (2021) 6:30**

<https://doi.org/10.1186/s41181-021-00141-0>


Following publication of the original article (Archibald and Allott 2021), the authors identified an error in Table 2 and Fig. 3. The correct table and figure are given below.

The original article (Archibald and Allott 2021) has been corrected.

**Table 2** Prominent examples of [<sup>18</sup>F]AIF radioconjugates discussed in this review

Target	[ <sup>18</sup> F]AIF Radioconjugate	Starting [ <sup>18</sup> F]F (GBq)	RCY (%)	A <sub>m</sub> (GBq/μmol)	Automated	Clinical Trial	Ref
SSTR	[ <sup>18</sup> F]AIF-NOTA-octreotide	41 - 42	26.1 ± 3.6	160.5 ± 75.3	Y	Y	(Allott et al., 2017; Hou et al., 2020; Long et al., 2019; Tshibangu et al., 2020).
	[ <sup>18</sup> F]AIF-FPSMA-11	18.5 - 100	15 - 24	58 - 544	Y	Y	(Giglio et al., 2018; Kersemans et al., 2018)
PSMA	[ <sup>18</sup> F]AIF-FPSMA-BCH	2.20 - 4.40	32.2 ± 4.5	13.2 - 18.9	N	Y	(Liu et al., 2019)
	[ <sup>18</sup> F]AIF-NOTA <sub>65</sub> -DUPA-Pep	0.87	79	3.4	N	N	(Malik et al., 2012)
	[ <sup>18</sup> F]AIF-Glu-urea-Lys(Ahx) <sub>3</sub> L3	40	25	27.0	Y	N	(Cleeren et al., 2016)
	[ <sup>18</sup> F]AIF-F16-093	0.37	54.4 ± 4.4	--	N	N	(Zha et al., 2021)
GZB	[ <sup>18</sup> F]AIF-mNOTA-GZP	10	17 - 25	45 - 90	N	N	(Goggi et al., 2020)
PD-L1	[ <sup>18</sup> F]AIF-NOTA-Z <sub>20</sub> -L1_1	--	15.1 ± 5.6	14.6 ± 6.5	N	N	(González Trotter et al., 2017)
IL2R	[ <sup>18</sup> F]AIF-RESCA-IL2	50	2.4 ± 1.6	910 ± 927	N	N	(van der Veen et al., 2020)
FAP	[ <sup>18</sup> F]AIF-NOTA-FAPI-74	2 - 10	--	20 - 50	Y	Y	(Giesel et al., 2021)
	[ <sup>18</sup> F]AIF-NOTA-FAPI-04	32 - 37	26.4 ± 1.5	49.4 ± 3.2	Y	Y	(Jiang et al., 2021)
HER2	[ <sup>18</sup> F]AIF-NOTA-Z <sub>HER2</sub> 2295	2 - 6	21.0 ± 5.7	7.7 ± 3.0	N	N	(Heskamp et al., 2012)
	[ <sup>18</sup> F]AIF-NOTA-MAL-MZ <sub>HER2</sub> 342	3.70	10	--	N	N	(Xu et al., 2017)
	[ <sup>18</sup> F]AIF-NOTA-Z <sub>HER2</sub> 2891	0.12	11 ± 4	0.35	N	N	(Glaser et al., 2013)
HER3	[ <sup>18</sup> F]AIF-NOTA-Z <sub>HER3</sub> 8698	0.25 - 0.30	9.9 - 27.4	6.0 - 11.9	N	N	(Da Pieve et al., 2016)
	[ <sup>18</sup> F]AIF-NODA-Z <sub>HER3</sub> 8698	0.46 - 0.50	9.9 - 27.4	5.5 - 18.4	N	N	(Da Pieve et al., 2016)
EGFR	[ <sup>18</sup> F]AIF-NOTA-Z <sub>EGFR</sub> 1907	37	15	1.5	N	N	(Su et al., 2014)
	[ <sup>18</sup> F]AIF-NOTA-PODS-Z <sub>EGFR</sub> 03115	0.18 - 0.20	11.0 - 12.7	3.0 - 4.4	N	N	(Da Pieve et al., 2020)
	[ <sup>18</sup> F]AIF-NODAGA-PODS-Z <sub>EGFR</sub> 03115	0.18 - 0.20	4.3 - 8.1	0.8 - 1.7	N	N	(Da Pieve et al., 2020)
Integrins	[ <sup>18</sup> F]AIF-NOTA-RGD <sub>2</sub>	0.55	17.9	11.1 - 14.7	N	N	(Liu et al., 2011)
	[ <sup>18</sup> F]AIF-NOTA-PRGD <sub>2</sub>	0.37 - 1.50	20 - 25	6.14	N	Y	(Lang et al., 2011; Wan et al., 2013; Zhou et al., 2017)
	[ <sup>18</sup> F]AIF-PEG <sub>35</sub> -A20FMDV2	11	19.3 ± 5.4	0.8 ± 0.2	N	N	(Hausner et al., 2014)
	[ <sup>18</sup> F]AIF-NODAGA-E[c(RGDfK)] <sub>2</sub>	2 - 6	20	1.8	N	N	(Dijkgraaf et al., 2013)
	[ <sup>18</sup> F]AIF-NOTA-PEG <sub>5</sub> -E[c(RGDfK)] <sub>2</sub>	0.37 - 0.74	40 - 60	14.8 - 37	N	N	(Guo et al., 2014)
	[ <sup>18</sup> F]AIF-NOTA-E[PEG <sub>5</sub> -c(RGDfK)] <sub>2</sub>	0.37 - 0.74	40 - 60	14.8 - 37	N	Y	(Guo et al., 2014)(Wu et al., 2018; Yu et al., 2015)
GRPR	[ <sup>18</sup> F]AIF-NODAGA-RM1	0.55	5.9 ± 1.1	1.85	N	N	(Liu et al., 2013)
	[ <sup>18</sup> F]AIF-NODAGA-AMBA	0.55	4.9 ± 1.3	1.85	N	N	(Liu et al., 2013)
	[ <sup>18</sup> F]AIF-NOTA-8-Aoc-BBN(7-14)NH <sub>2</sub>	1.10 - 3.30	50	10	N	N	(Dijkgraaf et al., 2012)
	[ <sup>18</sup> F]AIF-NOTA-4,7-lanthionine-BBN	0.20 - 0.32	50 - 60	63	N	N	(Carlucci et al., 2015)
	[ <sup>18</sup> F]AIF-NOTA-2,6-lanthionine-BBN	0.20 - 0.32	50 - 60	88	N	N	(Carlucci et al., 2015)
	[ <sup>18</sup> F]AIF-NOTA <sub>65</sub> -MATBBN	1.11	62.5 ± 2.1	30	N	N	(Pan et al., 2014)
CXCR4	[ <sup>18</sup> F]AIF-JMV5132	0.70 - 0.90	88	40 ± 4	N	N	(Chatalic et al., 2014)
	[ <sup>18</sup> F]AIF-NOTA-PZ-RM26	1 - 2	60 - 65	55	N	N	(Varasteh et al., 2013)
	[ <sup>18</sup> F]AIF-NOTA-pentixather	--	45.5 ± 13.3	≤24.8	N	N	(Poschenrieder et al., 2016)
	[ <sup>18</sup> F]AIF-NODA-NCS-pentixather	--	45.5 ± 13.3	≤24.8	N	N	(Poschenrieder et al., 2016)
	[ <sup>18</sup> F]AIF-NOTA-T140	0.85 - 1.04	58.0 ± 5.3	18.9 ± 1.1	N	N	(Yan et al., 2016)

Note: Some starting activities and molar activities (A<sub>m</sub>) were converted into GBq or calculated from data presented in the manuscript for the purposes of comparison

**Author details**

<sup>1</sup>Positron Emission Tomography Research Centre, Faculty of Health Sciences, University of Hull, Cottingham Road, Kingston upon Hull HU6 7RX, UK. <sup>2</sup>Department of Biomedical Sciences, Faculty of Health Sciences, University of Hull, Cottingham Road, Kingston upon Hull HU6 7RX, UK. <sup>3</sup>Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital, Castle Road, Cottingham HU16 5JQ, UK.

**Reference**

Archibald and Allott *EJNMMI Radiopharm. Chem.* (2021) 6:30 <https://doi.org/10.1186/s41181-021-00141-0>

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.